221 related articles for article (PubMed ID: 18429757)
1. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
2. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of allele variants of cytochrome CYP2C9 gene for anticoagulation therapy with warfarin].
Sirotkina OV; Ulitina AS; Taraskina AE; Kadinskaia MI; Vavilova TV; Pchelina SN; Shvarts EI
Kardiologiia; 2005; 45(4):61-3. PubMed ID: 15940194
[TBL] [Abstract][Full Text] [Related]
4. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
5. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
6. [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
Kondrat'eva LV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Kovalenko TF; Ostriakova EV; Reshetniak TM
Ter Arkh; 2010; 82(5):33-9. PubMed ID: 20597268
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
8. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
[TBL] [Abstract][Full Text] [Related]
9. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
10. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
[TBL] [Abstract][Full Text] [Related]
11. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
12. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
16. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
Taube J; Halsall D; Baglin T
Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
[TBL] [Abstract][Full Text] [Related]
19. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
[TBL] [Abstract][Full Text] [Related]
20. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.
Adcock DM; Koftan C; Crisan D; Kiechle FL
Arch Pathol Lab Med; 2004 Dec; 128(12):1360-3. PubMed ID: 15578879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]